Citadel Advisors’s Indivior Pharmaceuticals INDV Stock Holding History

Citadel Advisors’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.82M	Buy	117,500 +43,900	+60%	+$1.59M	﹤0.01%	4787
2026 Q1	$2.24M	Sell	73,600 -34,200	-32%	-$1.13M	﹤0.01%	5851
2025 Q4	$3.87M	Sell	107,800 -43,900	-29%	-$1.34M	﹤0.01%	4723
2025 Q3	$3.66M	Buy	151,700 +109,400	+259%	+$2.29M	﹤0.01%	4932
2025 Q2	$624K	Buy	42,300 +31,800	+303%	+$370K	﹤0.01%	8116
2025 Q1	$100K	Sell	10,500 -10,100	-49%	-$106K	﹤0.01%	11464
2024 Q4	$256K	Sell	20,600 -11,700	-36%	-$120K	﹤0.01%	9977
2024 Q3	$315K	Buy	32,300 +2,400	+8%	+$28.1K	﹤0.01%	9235
2024 Q2	$482K	Buy	29,900 +26,900	+897%	+$485K	﹤0.01%	8128
2024 Q1	$64.3K	Buy	+3,000	New	+$56.4K	﹤0.01%	11924

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's INDV Position: Q2 2026 in Review

Citadel Advisors reduced its Indivior Pharmaceuticals (INDV) stake by 25% in Q2 2026, selling an estimated $32.9M and leaving 2,667,827 shares worth $109M. The position accounts for 0.01% of the portfolio, ranked #911.

Citadel Advisors first reported a position in INDV in Q1 2024 and has held it in 10 quarters since. The position peaked at $110M in Q4 2025. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

Citadel Advisors held 2,667,827 shares of Indivior Pharmaceuticals worth $109M as of Q2 2026.
Citadel Advisors sold 906,217 Indivior Pharmaceuticals shares in Q2 2026, an estimated $32.9M.
Indivior Pharmaceuticals made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #911 holding.
Citadel Advisors first reported a position in Indivior Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Citadel Advisors's Indivior Pharmaceuticals position peaked at $110M in Q4 2025.
338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.